Today is #WorldCancerDay thank you @KTLA for this interview & raising cancer awareness @LuParker @glenwalkerktla @CSCancerCenter @OncoAlert @Larvol @OPENoncology @oncodaily @CParkMD @medicalwatchBC @MOASC_Office @OncoReporte @LinksCancer @OncBrothers

RT @montypal: We are getting awfully close to a full house for #SoCalGU25! Come join us at the @BalboaBayClub on Friday, Feb 28, for full d…

RT @GIMedOnc: Here ye, hear ye! ctDNA is prognostic in colorectal cancer. Still waiting for a trial demonstrating this can lead to interve…

RT @DrChoueiri: 1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tum…

RT @RManochakian: 🔥🚨@OncoAlert Hot off the press Just published @NEJM Results of #eNRGy trial of #Zenocutuzumab in #NRG1+ #Cancer that le…

RT @montypal: I would love to get some more poster submissions from our talented Southern California trainees! Please consider submitting y…

RT @montypal: A meeting for my #SoCal colleagues. No lengthy travel required. Join us in #NewportBeach to discuss the current status of cli…

@DanZhaoMD Summary of our @asco #GI25 abstr below. Thanks @VJOncology for the interview A collab b/t @CSCancerCenter @TempusAI @KristenCiombor Dr. Strickler @DukeCancer Dr. Valerin @UCIAntiCancer @mtmdphd

@neerajaiims @PavlosMsaouel @Huntsman_GU @ASCO @ConquerCancerFd @ziremozay @nsayeghmd @urotoday @PCFnews @OncoAlert @montypal @DrChoueiri @PGrivasMDPhD @shilpaonc @TiansterZhang @umangtalking @DrYukselUrun @AzadOncology @ASCOPres @PBarataMD Congrats to this trifecta of @ConquerCancerFd Merit Awards @ziremozay @nsayeghmd #DiyaGarg under the stellar mentorship of @neerajaiims @asco #GU24 ‼️

RT @TumorBoardTues: @DrGallent #Tumorboardtuesday 🙏Thank you @jgong15 & @DrGallent for🚶us through the subtelties & progress in the Tx of…

RT @EisaiGlobalOnc: There are several factors which may increase a person's chance of developing hepatocellular carcinoma (HCC). Here, doct…

RT @AmarUKishan: Proud to share work led by John Nikitas PGY-5 @UCLAHealth out in @TheLancetOncol We leveraged…

@MPishvaian @DrGallent How do we give triplet tx in the clinic? (ARPI + doce started w/in 6 weeks of #ADT in PEACE-1) @EdwinPosadasMD @CSCancerCenter and I start with ADT --> ARPI --> doce to assess tolerability sequentially rather than all together, institutional practices may vary? @montypal @CParkMD

@TumorBoardTues @DrGallent #TumorBoardTuesday Our colleagues in radiation onc @AnthonyNguyenMD @KamravaMD @_katelynatkins @ASTRO_Chair @l_ballas have been instrumental in supporting this paradigm @CSCancerCenter increasing use is seen across multiple cancer types indeed

RT @DrGallent: @MPishvaian Great point/question. mOS is a little deceiving to compare here since the PEACE-1 data is separated between low…

@MPishvaian @DrGallent Adding to this, TMPRSS-2 fusions may be prognostic w/predilections for certain racial groups. Other targets, e.g., SPOP seem to occur in TMPRSS2-ERG fusion neg #prostatecancer Genetic and biological drivers of prostate cancer disparities in Black men | Nature Reviews Urology

@MPishvaian @DrGallent @AnthonyNguyenMD Per STAMPEDE (arm H) RT was to start after randomization within 3–4 weeks after the last docetaxel dose.

RT @MPishvaian: @DrGallent #TumorBoardTuesday 🧐This makes sense to me in a gut-feeling kind of way: 👉With low volume disease, the primary…

RT @MPishvaian: @DrGallent #TumorBoardTuesday Yes‼️We saw this in neuroendocrine tumors, where a GA68-dotatate PET scan suddenly revealed…